. Author manuscript; available in PMC: 2017 Nov 6.

Published in final edited form as: J Thorac Oncol. 2011 Nov;6(11):1902–1906. doi: 10.1097/JTO.0b013e31822a7383

TABLE 3.

Association of VEGF Level with Overall Survival and Failure-Free Survival

		Overall Survival	Failure-Free Survival
		Hazard Ratio		Hazard Ratio
Parameter	p	95% CI	p	95% CI
Univariate Analysis
Log (VEGF Baseline)	0.057	1.32 (0.99, 1.77)	0.491	0.91 (0.71,1.18)
Multivariate Analysis^a
Log (Baseline VEGF)	0.035	1.42 (1.03,1.97)	0.843	0.97 (0.72, 1.32)
Log (Baseline VEGF)-Log (VEGF Cycle 1)	0.730	0.94 (0.64,1.37)	0.722	0.93 (0.63 1.38)
Performance (1–2 Vs. 0)	0.084	1.58 (0.94,2.66)	0.695	1.11 (0.67, 1.84)
Age (≥65 Yr Vs. <65 Yr)	0.077	1.59 (0.95,2.66)	0.438	1.22 (0.74, 2.01)

CI, confidence interval; VEGF, vascular endothelial growth factor.

Log baseline VEGF and Log (baseline VEGF)–Log (VEGF cycle 1) were forced into the final model with performance status, stage, age, treatment arm, sex, race, and histology as potential variables to be selected using stepwise algorithm with entry level of 0.10 and stay level of 0.10. Of 88 patients in the analysis, 78 patients were died; 85 failed (died or disease progressed).